BioTelemetry (NASDAQ:BEAT) Upgraded at ValuEngine

ValuEngine upgraded shares of BioTelemetry (NASDAQ:BEAT) from a hold rating to a buy rating in a report released on Wednesday morning, ValuEngine reports.

Other analysts have also issued research reports about the company. BidaskClub raised BioTelemetry from a strong sell rating to a sell rating in a research note on Thursday, September 12th. Zacks Investment Research lowered BioTelemetry from a buy rating to a hold rating in a research note on Friday, August 2nd. Sidoti decreased their target price on BioTelemetry from $95.00 to $87.00 and set a buy rating for the company in a report on Wednesday, July 31st. Raymond James downgraded BioTelemetry from an outperform rating to a market perform rating in a report on Friday, August 2nd. Finally, TheStreet downgraded BioTelemetry from a b- rating to a c+ rating in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of Buy and an average price target of $73.50.

Shares of NASDAQ:BEAT traded up $0.41 during trading on Wednesday, reaching $39.63. 140,084 shares of the company traded hands, compared to its average volume of 492,112. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 2.01 and a beta of 1.37. BioTelemetry has a 52-week low of $37.76 and a 52-week high of $80.92. The company has a current ratio of 2.19, a quick ratio of 2.09 and a debt-to-equity ratio of 0.54. The business’s fifty day moving average is $40.68 and its 200-day moving average is $48.88.

BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.08. The firm had revenue of $111.80 million during the quarter, compared to analyst estimates of $111.11 million. BioTelemetry had a return on equity of 22.98% and a net margin of 11.06%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.46 earnings per share. On average, sell-side analysts predict that BioTelemetry will post 1.97 earnings per share for the current fiscal year.

In related news, SVP Peter Ferola sold 44,276 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $39.03, for a total transaction of $1,728,092.28. Following the completion of the transaction, the senior vice president now owns 19,622 shares in the company, valued at $765,846.66. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 6.50% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of BioTelemetry by 1.3% during the second quarter. BlackRock Inc. now owns 5,032,734 shares of the medical research company’s stock valued at $242,325,000 after acquiring an additional 64,604 shares in the last quarter. Vanguard Group Inc. raised its holdings in BioTelemetry by 5.6% in the second quarter. Vanguard Group Inc. now owns 3,698,176 shares of the medical research company’s stock worth $178,067,000 after purchasing an additional 195,534 shares in the last quarter. Stephens Investment Management Group LLC raised its holdings in BioTelemetry by 42.4% in the second quarter. Stephens Investment Management Group LLC now owns 668,530 shares of the medical research company’s stock worth $32,190,000 after purchasing an additional 199,171 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in BioTelemetry by 0.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 586,023 shares of the medical research company’s stock worth $28,217,000 after purchasing an additional 2,709 shares in the last quarter. Finally, Carillon Tower Advisers Inc. raised its holdings in BioTelemetry by 0.5% in the second quarter. Carillon Tower Advisers Inc. now owns 481,207 shares of the medical research company’s stock worth $23,169,000 after purchasing an additional 2,575 shares in the last quarter. Institutional investors own 90.65% of the company’s stock.

About BioTelemetry

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Read More: What is net income?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.